Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more
Pharma Reaserch Prod Co Ltd (214450) - Total Assets
Latest total assets as of September 2025: ₩988.30 Billion KRW
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) holds total assets worth ₩988.30 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharma Reaserch Prod Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Pharma Reaserch Prod Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharma Reaserch Prod Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharma Reaserch Prod Co Ltd's total assets of ₩988.30 Billion consist of 64.8% current assets and 35.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 19.3% |
| Accounts Receivable | ₩38.46 Billion | 4.5% |
| Inventory | ₩57.33 Billion | 6.7% |
| Property, Plant & Equipment | ₩147.31 Billion | 17.2% |
| Intangible Assets | ₩19.54 Billion | 2.3% |
| Goodwill | ₩13.86 Billion | 1.6% |
Asset Composition Trend (2015–2024)
This chart illustrates how Pharma Reaserch Prod Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharma Reaserch Prod Co Ltd's current assets represent 64.8% of total assets in 2024, a decrease from 79.3% in 2015.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2024, up from 8.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 17.2% of total assets.
Pharma Reaserch Prod Co Ltd Competitors by Total Assets
Key competitors of Pharma Reaserch Prod Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharma Reaserch Prod Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Pharma Reaserch Prod Co Ltd generates 0.41x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Pharma Reaserch Prod Co Ltd generates $ 10.76 in net profit.
Pharma Reaserch Prod Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.51 | 4.01 | 3.55 |
| Quick Ratio | 6.74 | 3.38 | 2.97 |
| Cash Ratio | 0.00 | 0.13 | 0.00 |
| Working Capital | ₩599.60 Billion | ₩ 253.49 Billion | ₩ 91.55 Billion |
Pharma Reaserch Prod Co Ltd - Advanced Valuation Insights
This section examines the relationship between Pharma Reaserch Prod Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.23 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 59.9% |
| Total Assets | ₩855.70 Billion |
| Market Capitalization | $1.22 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pharma Reaserch Prod Co Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pharma Reaserch Prod Co Ltd's assets grew by 59.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharma Reaserch Prod Co Ltd (2015–2024)
The table below shows the annual total assets of Pharma Reaserch Prod Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩855.70 Billion | +59.86% |
| 2023-12-31 | ₩535.28 Billion | +11.97% |
| 2022-12-31 | ₩478.06 Billion | +11.79% |
| 2021-12-31 | ₩427.65 Billion | +33.71% |
| 2020-12-31 | ₩319.83 Billion | +18.49% |
| 2019-12-31 | ₩269.93 Billion | +4.55% |
| 2018-12-31 | ₩258.19 Billion | +36.58% |
| 2017-12-31 | ₩189.03 Billion | +5.41% |
| 2016-12-31 | ₩179.33 Billion | +5.92% |
| 2015-12-31 | ₩169.31 Billion | -- |